Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,813 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06971523RecruitingPhase 1/Phase 2
Study of CTS3497 for cancers missing a specific protein
This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06972576RecruitingPhase 1
EphA2-targeted CAR-DC and CAR-T cell therapy for advanced lung cancer
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
Hangzhou, ZhejiangAges 18–70 - NCT06973031Recruiting
Testing a new system for treating atrial fibrillation
This trial tests a new device that uses pulsed electric fields to treat atrial fibrillation (AF), a type of irregular heartbeat. It aims to see if this approach is safe and effective for people with AF that comes and goes or lasts for a short time.
KaiserslauternAges 18–80 - NCT06974929RecruitingPhase 1/Phase 2
Study of HRS-6209 combinations for breast cancer
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06976437RecruitingEarly Phase 1
Testing donor CAR-T cells for B-cell blood cancers
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
Zhenjiang, JiangsuAges 18 years+ - NCT06978192RecruitingPhase 2
Study for treating shingles pain with a special nerve block
This trial tests a combination of two treatments to reduce shingles pain that hasn't responded to standard medicines. It involves a nerve block to see if it can help people who have ongoing pain after shingles.
Zunyi, GuizhouAges 40–85 - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT06982807Recruiting
SMILE laser for stable nearsightedness
This study tests a new laser correction method called SMILE 4.0-VISULYZE to treat nearsightedness and other refractive errors. It may help people who are tired of glasses or contact lenses and want a quick, low-pain vision fix.
Nantong, JiangsuAges 18–40 - NCT06982989Recruiting
Wearable light therapy for pelvic pain
This study tests a wearable device that uses LED light to treat pelvic pain. It may be an option for people who want a non-medicine approach to managing their pain.
Beijing, Beijing MunicipalityAges 18–35 - NCT06983041Recruiting
Vaginal cooling device for yeast infection treatment
This trial tests a new vaginal cooling device to treat yeast infections. It may help relieve symptoms like itching, burning, or irritation without medication.
Jacksonville, FloridaAges 22–49 - NCT06983951Recruiting
Study of CAR T cells for light chain amyloidosis
This trial tests a type of immunotherapy called CAR T cells that target a protein called BCMA on abnormal cells. It is for people whose light chain amyloidosis has come back or not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07000682RecruitingEarly Phase 1
UTAA91 injection for systemic sclerosis study
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
Wuhan, HubeiAges 18 years+ - NCT07001956RecruitingEarly Phase 1
UTAA91 injection for difficult rheumatoid arthritis
This trial tests a new injection called UTAA91 for people with hard-to-treat rheumatoid arthritis. It's for those who have tried standard treatments without success.
Wuhan, HubeiAges 18 years+ - NCT07003074RecruitingPhase 3
New drug TQB2102 vs standard therapy for HER2+ breast cancer
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hefei, AnhuiAges 18–75 - NCT07004673Recruiting
PET/MR imaging for carotid artery plaque risk
This trial uses special PET/MR scans to look at fatty buildup in your neck arteries to see which ones might be dangerous. It could help doctors better understand your stroke risk and choose the right treatment.
Shanghai, Shanghai MunicipalityAges Any age - NCT07006012Recruiting
Study of RGL-305 for lymphoma with minimal residual disease
This trial tests if a new treatment called RGL-305 can help people with lymphoma who still have tiny amounts of cancer cells left after previous treatment. It is for those whose disease has responded to prior therapy but is not completely gone at the genetic level.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07010094Recruiting
Shockwave balloons for hardened heart artery blockages
This trial tests a special balloon that uses shock waves to crack calcium in heart arteries, making it easier to place a stent. It is for people with chest pain or signs of heart strain due to a single, severely blocked artery with dense calcium.
Fujian, XiamenAges 18–85 - NCT07011056RecruitingPhase 3
Study of a new drug for diffuse large B-cell lymphoma
This trial tests a new drug called Purinostat Mesylate for people with diffuse large B-cell lymphoma (a type of blood cancer) whose cancer has come back or not responded after at least two prior treatments. It aims to see if the drug can help shrink or control the cancer.
Chengdu, SichuanAges 18 years+ - NCT07016438Recruiting
Study of PAL-222 for stubborn skin ulcers
This trial tests a new treatment, PAL-222, for skin ulcers that haven't improved much after 4 weeks of standard care. It aims to see if PAL-222 can help these wounds heal better.
Kyoto, Shogoin-kawahara-cho, Sakyo-ku, KyotoAges 20 years+ - NCT07016802RecruitingPhase 1
Study of GenSci134 for growth hormone deficiency
This trial tests a new growth hormone treatment called GenSci134 in healthy adults and adults with growth hormone deficiency (AGHD). The goal is to see if it is safe and effective for people who need growth hormone replacement.
Beijing, Beijing MunicipalityAges 18–70 - NCT07021963RecruitingPhase 2
Long-term safety study of HRS-1893 for hypertrophic cardiomyopathy
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
Beijing, Beijing MunicipalityAges 18–85 - NCT07023315RecruitingPhase 3
Study of cadonilimab plus SOX before and after surgery for stomach cancer
This trial tests if adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery can help treat stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this combination improves outcomes for patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT07030790RecruitingPhase 1
Single dose study of KLA480 in healthy volunteers
This trial tests a single dose of KLA480 in healthy adults to see how the body processes it. It may help researchers understand the drug's safety and potential benefits.
Shanghai, Shanghai MunicipalityAges 18–45
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,813 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.